Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Collie GW"'
Autor:
Carlino L; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Astles PC; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Ackroyd B; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Ahmed A; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Chan C; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Collie GW; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Dale IL; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., O'Donovan DH; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Fawcett C; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., di Fruscia P; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Gohlke A; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Guo X; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Hao-Ru Hsu J; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Kaplan B; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Milbradt AG; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Northall S; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Petrović D; Hit Discovery, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg 431 50, Sweden., Rivers EL; Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Underwood E; Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Webb A; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2024 Jun 13; Vol. 67 (11), pp. 8962-8987. Date of Electronic Publication: 2024 May 15.
Autor:
Collie GW; R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Börjesson U; R&D, AstraZeneca, Gothenburg 431 83, Sweden., Chen Y; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China., Dong Z; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China., Di Fruscia P; R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Gohlke A; R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Hoyle A; R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Hunt TA; R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Jesani MH; R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Luo H; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China., Luptak J; R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Milbradt AG; R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Narasimhan P; R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Packer M; R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Patel S; R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Qiao J; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P.R. China., Storer RI; R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Stubbs CJ; R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Tart J; R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Truman C; R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Wang AT; R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Wheeler MG; R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Winter-Holt J; R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
Publikováno v:
ACS medicinal chemistry letters [ACS Med Chem Lett] 2024 Jun 07; Vol. 15 (7), pp. 1151-1158. Date of Electronic Publication: 2024 Jun 07 (Print Publication: 2024).
Autor:
Collie GW; AstraZeneca, Cambridge CB2 0AA, U.K., Clark MA; X-Chem, Inc., Waltham, Massachusetts 02453, United States., Keefe AD; X-Chem, Inc., Waltham, Massachusetts 02453, United States., Madin A; AstraZeneca, Cambridge CB2 0AA, U.K., Read JA; AstraZeneca, Cambridge CB2 0AA, U.K., Rivers EL; AstraZeneca, Cambridge CB2 0AA, U.K., Zhang Y; X-Chem, Inc., Waltham, Massachusetts 02453, United States.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2024 Jan 25; Vol. 67 (2), pp. 864-884. Date of Electronic Publication: 2024 Jan 10.
Autor:
Yoo SH; Univ. Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248, IECB, 2 rue Robert Escarpit, 33607, Pessac, France. g.guichard@iecb.u-bordeaux.fr.; Department of Chemistry, Chonnam National University, Gwangju 61186, Republic of Korea., Buratto J; Univ. Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248, IECB, 2 rue Robert Escarpit, 33607, Pessac, France. g.guichard@iecb.u-bordeaux.fr., Roy A; Univ. Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248, IECB, 2 rue Robert Escarpit, 33607, Pessac, France. g.guichard@iecb.u-bordeaux.fr., Pasco M; Univ. Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248, IECB, 2 rue Robert Escarpit, 33607, Pessac, France. g.guichard@iecb.u-bordeaux.fr., Pulka-Ziach K; Faculty of Chemistry, University of Warsaw, 02093 Warsaw, Poland., Collie GW; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, UK. gavin.collie@astrazeneca.com., Guichard G; Univ. Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248, IECB, 2 rue Robert Escarpit, 33607, Pessac, France. g.guichard@iecb.u-bordeaux.fr.
Publikováno v:
Organic & biomolecular chemistry [Org Biomol Chem] 2024 Jan 24; Vol. 22 (4), pp. 731-734. Date of Electronic Publication: 2024 Jan 24.
Autor:
Michaelides IN, Collie GW
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2023 Nov 23; Vol. 66 (22), pp. 15564. Date of Electronic Publication: 2023 Nov 04.
Autor:
Michaelides IN; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Collie GW; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Börjesson U; Discovery Sciences, R&D, AstraZeneca, 43183 Mölndal, Sweden., Vasalou C; DMPK, Oncology R&D, AstraZeneca, Boston, Waltham, Massachusetts 02451, United States., Alkhatib O; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Barlind L; Discovery Sciences, R&D, AstraZeneca, 43183 Mölndal, Sweden., Cheung T; Bioscience, Oncology R&D, AstraZeneca, Boston, Waltham, Massachusetts 02451, United States., Dale IL; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Embrey KJ; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Hennessy EJ; Medicinal Chemistry, Oncology R&D, AstraZeneca, Boston, Waltham, Massachusetts 02451, United States., Khurana P; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Koh CM; Bioscience, Oncology R&D, AstraZeneca, Boston, Waltham, Massachusetts 02451, United States., Lamb ML; Computational Chemistry, Oncology R&D, AstraZeneca, Boston, Waltham, Massachusetts 02451, United States., Liu J; Discovery Sciences, R&D, AstraZeneca, 43183 Mölndal, Sweden., Moss TA; Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., O'Neill DJ; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Phillips C; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Shaw J; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Snijder A; Discovery Sciences, R&D, AstraZeneca, 43183 Mölndal, Sweden., Storer RI; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Stubbs CJ; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Han F; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, 100176 Beijing, People's Republic of China., Li C; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, 100176 Beijing, People's Republic of China., Qiao J; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, 100176 Beijing, People's Republic of China., Sun DQ; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, 100176 Beijing, People's Republic of China., Wang J; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, 100176 Beijing, People's Republic of China., Wang P; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, 100176 Beijing, People's Republic of China., Yang W; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, 100176 Beijing, People's Republic of China.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2023 Jul 13; Vol. 66 (13), pp. 8782-8807. Date of Electronic Publication: 2023 Jun 21.
Autor:
Michaelides IN; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom., Collie GW; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom.
Publikováno v:
Journal of medicinal chemistry [J Med Chem] 2023 Mar 09; Vol. 66 (5), pp. 3173-3194. Date of Electronic Publication: 2023 Feb 23.
Autor:
Pierrat OA; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Liu M; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Collie GW; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK.; Division of Structural Biology, The Institute of Cancer Research, London, SW3 6JB, UK., Shetty K; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK.; Division of Structural Biology, The Institute of Cancer Research, London, SW3 6JB, UK., Rodrigues MJ; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK.; Division of Structural Biology, The Institute of Cancer Research, London, SW3 6JB, UK., Le Bihan YV; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK.; Division of Structural Biology, The Institute of Cancer Research, London, SW3 6JB, UK., Gunnell EA; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK.; Division of Structural Biology, The Institute of Cancer Research, London, SW3 6JB, UK., McAndrew PC; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Stubbs M; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Rowlands MG; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Yahya N; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Shehu E; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Talbot R; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Pickard L; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Bellenie BR; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Cheung KJ; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Drouin L; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Innocenti P; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Woodward H; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Davis OA; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Lloyd MG; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Varela A; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Huckvale R; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Broccatelli F; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Carter M; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Galiwango D; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Hayes A; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Raynaud FI; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Bryant C; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Whittaker S; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Rossanese OW; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Hoelder S; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., Burke R; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK., van Montfort RLM; Division of Cancer Therapeutics, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, SM2 5NG, UK. rob.vanmontfort@icr.ac.uk.; Division of Structural Biology, The Institute of Cancer Research, London, SW3 6JB, UK. rob.vanmontfort@icr.ac.uk.
Publikováno v:
Scientific reports [Sci Rep] 2022 Nov 03; Vol. 12 (1), pp. 18633. Date of Electronic Publication: 2022 Nov 03.
Autor:
Collie GW; Discovery Sciences, R&D, AstraZeneca, Cambridge, U.K. Electronic address: gavin.collie@astrazeneca.com., Barlind L; Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Bazzaz S; X-Chem, Inc., Waltham, MA 02453, United States., Börjesson U; Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Dale IL; Discovery Sciences, R&D, AstraZeneca, Cambridge, U.K., Disch JS; X-Chem, Inc., Waltham, MA 02453, United States., Habeshian S; X-Chem, Inc., Waltham, MA 02453, United States., Jetson R; X-Chem, Inc., Waltham, MA 02453, United States., Khurana P; Discovery Sciences, R&D, AstraZeneca, Cambridge, U.K., Madin A; Discovery Sciences, R&D, AstraZeneca, Cambridge, U.K., Michaelides IN; Discovery Sciences, R&D, AstraZeneca, Cambridge, U.K., Peng L; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, PR China., Snijder A; Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Stubbs CJ; Discovery Sciences, R&D, AstraZeneca, Cambridge, U.K.
Publikováno v:
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2022 Nov 01; Vol. 75, pp. 128948. Date of Electronic Publication: 2022 Aug 17.
Autor:
Yoo SH; Univ. Bordeaux, CNRS, Bordeaux INP, CBMN, UMR5248, IECB, 2 rue Robert Escarpit, F-33600 Pessac, France., Buratto J; Univ. Bordeaux, CNRS, Bordeaux INP, CBMN, UMR5248, IECB, 2 rue Robert Escarpit, F-33600 Pessac, France., Roy A; Univ. Bordeaux, CNRS, Bordeaux INP, CBMN, UMR5248, IECB, 2 rue Robert Escarpit, F-33600 Pessac, France., Morvan E; Univ. Bordeaux, CNRS, INSERM, IECB, UAR3033, US001, F-33600 Pessac, France., Pasco M; Univ. Bordeaux, CNRS, Bordeaux INP, CBMN, UMR5248, IECB, 2 rue Robert Escarpit, F-33600 Pessac, France., Pulka-Ziach K; Faculty of Chemistry, University of Warsaw, Pasteura 1, 02093 Warsaw, Poland., Lombardo CM; Univ. Bordeaux, CNRS, Bordeaux INP, CBMN, UMR5248, IECB, 2 rue Robert Escarpit, F-33600 Pessac, France., Rosu F; Univ. Bordeaux, CNRS, INSERM, IECB, UAR3033, US001, F-33600 Pessac, France., Gabelica V; Univ. Bordeaux, CNRS, INSERM, IECB, UAR3033, US001, F-33600 Pessac, France.; Univ. Bordeaux, CNRS, INSERM, ARNA, UMR5320, U1212, IECB, F-33600 Bordeaux, France., Mackereth CD; Univ. Bordeaux, CNRS, INSERM, ARNA, UMR5320, U1212, IECB, F-33600 Bordeaux, France., Collie GW; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, U.K., Guichard G; Univ. Bordeaux, CNRS, Bordeaux INP, CBMN, UMR5248, IECB, 2 rue Robert Escarpit, F-33600 Pessac, France.
Publikováno v:
Journal of the American Chemical Society [J Am Chem Soc] 2022 Sep 07; Vol. 144 (35), pp. 15988-15998. Date of Electronic Publication: 2022 Aug 23.